Scopus BioPharma

Scopus Biopharma, Inc. is a biopharmaceutical company, which engages in the development of transformational therapeutics targeting serious diseases with unmet medical needs. Its drug candidates consist of a combination of cannabidiol-mediated, opioid-sparing anesthetics, synthesis of cannabinoids, and cannabinoid receptor mediating compounds for the treatment of systemic sclerosis. The company was founded on April 18, 2017 and is headquartered in New York, NY.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Scopus Biopharma, Inc. is a biopharmaceutical company, which engages in the development of therapeutics targeting diseases with unmet medical needs. The company was founded on April 18, 2017 and is headquartered in New York, NY.

DUET-102 in Combination with PD-1 Blockade Demonstrates Significant Anti-Tumor Activity in Models of Malignant Glioma

Scopus BioPharma's Subsidiary — Duet BioTherapeutics — Presents Compelling New Data for a Novel Treatment for Malignant Glioma at 38th Annual Meeting of the Society for Immunotherapy of Cancer

NEW YORK, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Scopus BioPharma Inc. (OTCQB: “SCPS ”), a biotechnology company developing transformational therapeutics for serious diseases with significant unmet medical need, and its subsidiary, Duet BioTherapeutics Inc., which is developing novel immunotherapies to overcome treatment-resistant cancers, today announced that Marcin Kortylewski, Ph.D., Co-Founder and Senior Scientific Advisor of Duet and Professor of Immuno-Oncology at City of Hope, will be presenting at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (“SITC”). SITC is being held from November 3-5, 2023, in San Diego, California.

Scopus BioPharma's Subsidiary — Duet BioTherapeutics — to Present at the 38th Annual Meeting of the Society for Immunotherapy of Cancer

NEW YORK, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Scopus BioPharma Inc. (Nasdaq: “SCPS”), a biopharmaceutical company developing transformational therapeutics for serious diseases with significant unmet medical need, and its pure-play immuno-oncology subsidiary, Duet BioTherapeutics, today announced that key scientific data will be will be presented at the 37th Annual Meeting and Exposition of the Society for Immunotherapy of Cancer (“SITC”).

Scopus BioPharma's Subsidiary — Duet BioTherapeutics — Announces Key Scientific Data to be Presented at the 37th Annual Meeting and Exposition of the Society for Immunotherapy of Cancer

Warrants to Purchase Approximately 21 Million Scopus Shares Eliminated

Scopus Biopharma Completes Recapitalization Designed To Enhance Shareholder Value

Raphael (“Rafi”) Hofstein, Ph.D. Brings Invaluable Experience to Scopus BioPharma Raphael (“Rafi”) Hofstein, Ph.D. Brings Invaluable Experience to Scopus BioPharma

Scopus BioPharma Announces Biotechnology Industry Leader Rejoins Board of Directors

Alan Horsager, Ph.D., President and Chief Executive Officer of Duet, to Present on TLR9 Activation and STAT3 Inhibition: A Bifunctional Approach to Immuno-Oncology

Scopus BioPharma's Subsidiary — Duet BioTherapeutics — to Present at the 3rd Annual STING & TLR-Targeting Therapies Summit

Overwhelming Majority of Shares Voted by Unaffiliated Stockholders were in Favor of Scopus' Director Nominees

Scopus BioPharma Provides Update Following Annual Meeting of Stockholders

NEW YORK and JERUSALEM, Jan. 6, 2022 /PRNewswire/ -- Dr. Morris C. Laster ("Dr. Laster"), who, together with other proxy participants, beneficially owns 6,006,000 shares of common stock, par value $0.001, of Scopus BioPharma Inc. (Nasdaq: SCPS) ("Scopus" or the "Company"), announced today that stockholders of the Company have elected Dr. Laster's two director nominees, Mordechai Saar Hacham and Joshua Levine to the Company's Board of Directors at the Company's 2021 Annual Meeting of Stockholders (the "Annual Meeting").

DR. MORRIS C. LASTER WINS PROXY CONTEST AS STOCKHOLDERS ELECT HIS NOMINEES TO SCOPUS BIOPHARMA INC.

Latest Legal Claims by Laster Actually Call into Question his Stock Ownership

Scopus BioPharma Issues Open Letter to Stockholders Detailing Morris Laster's Campaign Against the Company

Company's Director Nominees are Highly Qualified and Experienced with Track Records of Guiding Early-Stage Life Science Companies

Scopus BioPharma Sends Letter Urging Stockholders to Vote “FOR ALL” of the Company's Director Nominees on the WHITE Proxy Card

NEW YORK and JERUSALEM, Dec. 6, 2021 /PRNewswire/ -- Dr. Morris C. Laster ("Dr. Laster"), who, together with the other proxy participants, beneficially owns 6,006,000 shares of common stock, par value $0.001 in Scopus BioPharma Inc. (Nasdaq: SCPS) ("Scopus" or the "Company"), issued an open letter to Scopus stockholders today in connection with the Company's upcoming Annual Meeting.

Dr. Morris C. Laster Issues An Open Letter To Scopus BioPharma Inc. Stockholders In Connection With Upcoming Annual Meeting

NEW YORK, Oct. 08, 2021 (GLOBE NEWSWIRE) -- Scopus BioPharma Inc. (Nasdaq: “SCPS”), a clinical-stage biopharmaceutical company developing transformational therapeutics for serious diseases with significant unmet medical need, today announced that, on October 8, 2021, its 2021 Annual Meeting of Stockholders (the “Annual Meeting”) was adjourned to 1:00 p.m., Eastern time, on Friday, November 5, 2021, without any business being conducted, pursuant to a Stipulation and Court Order approved by the Delaware Court of Chancery between Scopus and Morris C. Laster, M.D. in connection with Dr. Laster's pending claims against Scopus in the Delaware Court of Chancery. Notwithstanding the Stipulation and Court Order requiring Dr. Laster to cause all shares of Scopus common stock held by him to be present in person or by proxy at the Annual Meeting and any adjournments thereof exclusively for the purposes of establishing a quorum at the meeting, Dr. Laster failed to satisfy this requirement by both not attending the Annual Meeting in person and not making his shares present by proxy.

Scopus BioPharma Announces Adjournment of Annual Meeting of Stockholders

Scopus to present on the recent launch of Duet Therapeutics,  its wholly-owned subsidiary focused on immuno-oncology

Scopus BioPharma to Present at the LD Micro Main Event

NEW YORK, Oct. 01, 2021 (GLOBE NEWSWIRE) -- Scopus BioPharma Inc. (Nasdaq: “SCPS”), a clinical-stage biopharmaceutical company, announced today that it is retaining Boies Schiller Flexner LLP to conduct a market manipulation investigation.

Scopus BioPharma Retaining Counsel to Investigate Unusual Market Activity

Scopus BioPharma to Present at MicroCap Rodeo's Fall Harvest Best Ideas Conference

Data from two different studies benchmark Duet's proprietary bifunctional oligonucleotides against immune checkpoint inhibitors (“Checkpoint Inhibitors”) in lymphoma and prostate tumor models in mice

Scopus BioPharma's Subsidiary — Duet Therapeutics — Announces Release of Preclinical Data Being Presented at 17th Annual Meeting of the Oligonucleotide Therapeutics Society

Duet releases video depicting mechanism of action for its proprietary CpG-STAT3 inhibitors to coincide with Duet presentations at OTS Meeting Duet releases video depicting mechanism of action for its proprietary CpG-STAT3 inhibitors to coincide with Duet presentations at OTS Meeting

Scopus BioPharma's Subsidiary Duet Therapeutics Set to Release Scientific Data During the 17th Annual Meeting of the Oligonucleotide Therapeutics Society

Scopus BioPharma's Subsidiary — Duet Therapeutics — Set to Release Scientific Data During the 17th Annual Meeting of the Oligonucleotide Therapeutics Society

NEW YORK, Sept. 28, 2021 (GLOBE NEWSWIRE) -- Scopus BioPharma Inc. (Nasdaq: “SCPS”), a clinical-stage biopharmaceutical company developing transformational therapeutics for serious diseases with significant unmet medical need, announced today that, pursuant to a stipulation with Morris C. Laster, M.D. in connection with pending claims brought by Dr. Laster in the Delaware Court of Chancery, the company intends to convene, and then immediately adjourn, the company's scheduled October 8, 2021 Annual Meeting of Stockholders (the “Annual Meeting”) such that the Annual Meeting will be held and the vote on the items of business to be considered at the Annual Meeting will be taken no earlier than 14 days after a decision on the merits or a final settlement between the parties. The company and Dr. Laster intend to conduct discussions in an effort to seek to resolve the disputes between the parties and have also agreed to an expedited timeline for resolving the Delaware court action.

Scopus BioPharma to Adjourn 2021 Annual Meeting of Stockholders

Alan Horsager, Ph.D., President and Chief Executive Officer of Duet Therapeutics, will present on CpG-STAT3 RNA Silencing and Antisense inhibitors

Scopus BioPharma's Subsidiary — Duet Therapeutics — to Present at the 17th Annual Meeting of the Oligonucleotide Therapeutics Society

New patent covers compound and composition and methods of use for CpG-STAT3 Antisense inhibitor (CpG-STAT3ASO)

China National Intellectual Property Administration Grants New Patent Covering DUET-02, One of Three Key CpG-STAT3 Inhibitors Comprising the Duet Platform

XTL Biopharmaceuticals

JERUSALEM, Sept. 20, 2021 /PRNewswire/ -- Dr. Morris C.

Dr. Morris C. Laster Files Preliminary Proxy Statement Nominating Two Highly-Qualified Individuals For Election To Board At Scopus BioPharma Inc.'s 2021 Annual Meeting

Dr. Kortylewski is the Leading Authority on Bi-Functional Oligonucleotide Cancer Therapeutics and a Professor in the Department of Immuno-Oncology at the Beckman Research Institute at City of Hope National Medical Center

Scopus BioPharma's Subsidiary — Duet Therapeutics — Announces Appointment of Marcin Kortylewski, Ph.D. as Senior Scientific Advisor

Alan Horsager, Ph.D., President and Chief Executive Officer of Duet, to Present on Clinical Development of CpG-STAT3 Inhibitors Alan Horsager, Ph.D., President and Chief Executive Officer of Duet, to Present on Clinical Development of CpG-STAT3 Inhibitors

Scopus BioPharma's Subsidiary — Duet Therapeutics — to Present at the 14th Annual RNA Consortium Meeting

Scopus BioPharma Inc (NASDAQ: SCPS) has launched Duet Therapeutics that integrates the management and clinical development of the immunotherapy assets of Scopus and Olimmune. Related Content: Scopus BioPharma Adds Oligonucleotide Cancer Therapeutics With Olimmune Acquisition.

News for Scopus BioPharma Stock (SCPS)